News
Pharma Bosses See Inflation As The No. 1 Challenge In 2023
According to a survey of executives done by GlobalData Healthcare, the pharmaceutical industry's top concern heading into 2023 is INFLATION.
The study, which was conducted between October 26 and November 23, found that CEOs ranked inflation as the biggest barrier...
News
5 Factors to Consider When Choosing Specialist Clinical Software
Choosing the right specialist clinical software is essential for any healthcare organization. The software will help you manage your patients and their medical records and provide other important features. There are many software options on the market, so deciding...
News
Strategies for Managing Dysphagia Symptoms
Dysphagia is a condition that people can develop for a wide range of reasons. The main symptom of dysphagia is difficulties with swallowing foods and liquids. Being unable to swallow a lot of food can quickly become a problem...
Drug Research
Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers
Bruker Corporation and Switzerland-based Biognosys AG announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys. Several of Biognosys’ earlier investors have sold...
Drug Research
ASLAN, Thermo Fisher Join To Manufacture High Concentration Formulation Of Eblasakimab
ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, and Thermo Fisher Scientific Inc, the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of...
Drug Research
Hong Kong University Develops Bone Anabolic Therapy Aptamer
The molecular target for bone anabolic therapy has been discovered by a research team headed by Hong Kong Baptist University (HKBU), utilising a particular aptamer that acts as an inhibitor of sclerostin, a protein that inhibits bone development.
In comparison...
Drug Research
Nykode Therapeutics and Richter-Helm BioLogics Enter Manufacturing Partnership
Nykode Therapeutics, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, has entered into a manufacturing partnership with Richter-Helm BioLogics to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio.
“We are excited about...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read